|View printer-friendly version|
|August 07, 2005 11:39 a.m.|
|Teva Receives Follow-Up Approvable Letter from FDA Regarding Agilect®|
Jerusalem, Israel, August 7, 2005 - August 5, 2005 - Teva Pharmaceutical Industries Ltd.(Nasdaq: TEVA). Last evening, Teva received a letter from the FDA regarding its NDA for Agilect®. While the letter reiterates the FDA's position that the application is approvable, there remain a number of issues that Teva believed it had resolved with its submissions, but as to which the FDA continues to have concerns. The FDA has indicated its interest in a follow-up meeting to discuss issues raised in the letter. Teva intends to meet promptly with the FDA and to work closely with the agency to resolve these issues.